4.95
4.95 (0%)
As of Apr 17, 2025
Karyopharm Therapeutics Inc. [KPTI]
Source:
Company Overview
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer. Our scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm.
| Country | United States |
| Headquarters | newton, massachusetts |
| Phone Number | (617) 658-0600 |
| Industry | manufacturing |
| CEO | Richard Paulson |
| Website | www.karyopharm.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $145.2 |
| Operating Profit | $-119.4 |
| Net Income | $-76.4 |
| Net Cash | $9.6 |
Profit Ratios
| Gross Margin | $145.2 |
| Operating Margin | -82.2 |
| Profit as % of Revenues | -190.1% |
| Profit as % of Assets | -37.8% |
| Profit as % of Stockholder Equity | 41.1% |
Management Effectiveness
| Return on Equity | 41.1% |
| Return on Assets | -46.5% |
| Turnover Ratio | 71.8% |
| EBITA | $-119.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $164.4 |
| Total Liabilities | $350.4 |
| Operating Cash Flow | $-127.5 |
| Investing Cash Flow | $95.5 |
| Financing Cash Flow | $41.6 |
